For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

TORONTO, June 10, 2019 /CNW/ - Detailed results from REWIND, the Trulicity ® (dulaglutide) cardiovascular outcome trial, showed a significant 12 per cent reduction in major cardiovascular events ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

Two drugs commonly known as Mounjaro and Trulicity, will not be available for online sale to non-Canadian residents.

VICTORIA - British Columbia’s Health Ministry is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic. The ...

From a mean baseline HbA 1c of 8.2%, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide. People ...

Dulaglutide decreases estimated glomerular filtration rate (eGFR) and proteinuria among youth with type 2 diabetes, according to the results of a study published in Diabetes Care. Youth with type 2 ...

Participants were randomly assigned to either switch to tirzepatide or to escalate their dulaglutide dose. Results indicated that after 40 weeks, the reduction in HbA1c levels was significantly more ...